Immunome Can Take The Fight To Competitors With Varegacestat

Group 1 - Many biotechs in the antibody-drug conjugate (ADC) space experienced a pullback throughout much of 2024, which offset a rally that occurred in late 2023 and early 2024 [1] - Immunome (NASDAQ: IMNM) was one of the companies affected by this downturn, despite a buy rating issued in April 2024 [1]